187 related articles for article (PubMed ID: 38334611)
1. EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor.
Sprinzen L; Garcia F; Mela A; Lei L; Upadhyayula P; Mahajan A; Humala N; Manier L; Caprioli R; Quiñones-Hinojosa A; Casaccia P; Canoll P
Cells; 2024 Jan; 13(3):. PubMed ID: 38334611
[TBL] [Abstract][Full Text] [Related]
2. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
Sears TK; Horbinski CM; Woolard KD
J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
[TBL] [Abstract][Full Text] [Related]
3. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
4. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
5. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract][Full Text] [Related]
6. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.
Garrett MC; Albano R; Carnwath T; Elahi L; Behrmann CA; Pemberton M; Woo D; O'Brien E; VanCauwenbergh B; Perentesis J; Shah S; Hagan M; Kendler A; Zhao C; Paranjpe A; Roskin K; Kornblum H; Plas DR; Lu QR
Sci Rep; 2023 Aug; 13(1):12433. PubMed ID: 37528157
[TBL] [Abstract][Full Text] [Related]
7. Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat.
Chang CM; Ramesh KK; Huang V; Gurbani S; Kleinberg LR; Weinberg BD; Shim H; Shu HG
Tomography; 2023 May; 9(3):942-954. PubMed ID: 37218937
[TBL] [Abstract][Full Text] [Related]
8. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
9. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
12. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair.
Dow J; Krysztofiak A; Liu Y; Colon-Rios DA; Rogers FA; Glazer PM
Mol Cancer Res; 2021 Dec; 19(12):2057-2067. PubMed ID: 34535560
[TBL] [Abstract][Full Text] [Related]
13. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
16. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
[TBL] [Abstract][Full Text] [Related]
17. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
[TBL] [Abstract][Full Text] [Related]
18. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
Gao Y; de Wit M; Struys EA; van der Linde HCZ; Salomons GS; Lamfers MLM; Willemsen R; Sillevis Smitt PAE; French PJ
PLoS One; 2018; 13(6):e0199737. PubMed ID: 29953513
[TBL] [Abstract][Full Text] [Related]
19. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas.
Ishi Y; Takamiya S; Seki T; Yamazaki K; Hida K; Hatanaka KC; Ishida Y; Oda Y; Tanaka S; Yamaguchi S
Brain Tumor Pathol; 2020 Jul; 37(3):81-88. PubMed ID: 32529280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
